Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2006

View Archived Issues

Zebularine improves survival in mouse model of T-cell lymphoma

LY-354740 prodrug, LY-544344, has greater behavioral effects in vivo

Glycyl-glutamine suppresses nicotine addiction in rats

N-Acetylcysteine well tolerated in cocaine-dependent individuals

OPT-80 shows efficacy in CDAD in phase IIa studies

Arimoclomol open-label extension study opens for ALS patients

NE-180 studied in phase I trial

OncoVEX(GM-CSF) studied for malignant melanoma, head and neck cancer

Advances in diagnostic tests for Alzheimer's disease

Acrux acquires rights to commercialize contraceptive spray

Novel Gb3 synthetic analogue demonstrates anti-HIV promise

Potent antimicrobial activity of a re-engineered vancomycin

Initiation of Veronate rolling BLA

AT-2101 receives orphan drug designation for Gaucher's disease

Novavax enters research collaboration with U. of Pittsburgh

Lilly and Boehringer Ingelheim amend Yentreve/AriClaim agreements

Phase I study of MEM-3454 completes dosing

sBLA filed for adjuvant Herceptin in early-stage HER2-positive breast cancer

Keryx inlicenses novel phosphate binder Zerenex

OSI begins phase I study with glucokinase activator PSN-010

Januvia NDA accepted for review

Accentia's IND for SinuNase on track

FDA lifts clinical hold on Tysabri in multiple sclerosis

Resistance profiling of a novel anti-V3 monoclonal antibody

ANA-380 achieves robust viral load reduction in lamivudine-resistant HBV patients

Novel agents reported for arthritis and other inflammatory disorders

Novel 5-HT2C receptor agonists emerge from Athersys R&D

Disruption of coordinated heart growth and angiogenesis contributes to heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.